G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics

Pharmacogenomics

Volumn 9, Issue 10, 2008, Pages 1429-1436

  Kohlrausch, Fabiana B ^a   Salatino Oliveira, Angélica ^a   Gama, Clarissa S ^a   Lobato, Maria Inês ^a   Belmonte de Abreu, Paulo ^a   Hutz, Mara H ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Clozapine; GNB3 gene; Pharmacogenetics; Polymorphisms

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CLOZAPINE; CYTOSINE; GUANINE NUCLEOTIDE BINDING PROTEIN; LITHIUM; NEUROLEPTIC AGENT; PAROXETINE; THYMINE; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GRAND MAL SEIZURE; HEREDITY; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROTOXICITY; NUCLEIC ACID BASE SUBSTITUTION; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCHIZOPHRENIA;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; BRAZIL; CLOZAPINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROTRIMERIC GTP-BINDING PROTEINS; HOMOZYGOTE; HUMANS; LOGISTIC MODELS; MALE; POLYMORPHISM, GENETIC; PROTEIN SUBUNITS; SCHIZOPHRENIA;

EID: 55449114291     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.10.1429     Document Type: Article

References (36)

1. Sawa A, Snyder SH: Schizophrenia: diverse approaches to a complex disease. Science 296, 692-695 (2002).
2. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60, 553-564 (2003).
3. Wilffert B, Zaal R, Brouwers JR: Pharmacogenetics as a tool in the therapy of schizophrenia. Pharm. World Sci. 27, 20-30 (2005).
4. Arranz MJ, Kerwin RW: Neurotransmitter-related genes and antipsychotic response: pharmacogenetics meets psychiatric treatment. Ann. Med. 32, 128-133 (2000).
5. Arranz MJ, Munro J, Osborne S, Collier D, Kerwin RW: Applications of pharmacogenetics in psychiatry: personalisation of treatment. Expert Opin. Pharmacother. 2, 537-542 (2001).
6. Basile VS, Masellis M, Potkin SG, Kennedy JL: Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum. Mol. Genet. 11, 2517-2530 (2002).
7. Malhotra AK, Murphy GM Jr, Kennedy JL: Pharmacogenetics of psychotropic drug response. Am. J. Psychiatry 161, 780-796 (2004).
8. Siffert W, Rosskopf D, Siffert G et al.: Association of a human G-protein β3 subunit variant with hypertension. Nat. Genet. 18, 45-48 (1998).
9. Arranz MJ, de Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 12, 707-747 (2007).
10. Teitler M, Herrick-Davis K, Purohit A: Constitutive activity of G-protein coupled receptors: emphasis on serotonin receptors. Curr. Top. Med. Chem. 2, 529-538 (2002).
11. Müller DJ, de Luca V, Sicard T et al.: Suggestive association between the C825T polymorphism of the G-protein β3 subunit gene ( GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur. Neuropsychopharmacol. 15, 525-531 (2005).
12. Anttila S, Kampman O, Illi A, Rontu R, Lehtimäki T, Leinonen E: Association between 5-HT2A, TPII1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach. BMC Psychiatry 7, 22-27 (2007).
13. Wang YC, Bai YM, Chen JY et al.: C825T polymorphism in the human G protein β3 subunit is associated with long-term clozapine treatment-induced body weight change in the Chinese population. Pharmacogenet. Genomics 15, 743-748 (2005).
14. Bishop JR, Ellingrod VL, Moline J, Miller D: Pilot study of the G-protein β3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med. Sci. Monit. 12, BR47-BR50 (2006).
15. Zembrzuski VM, Callegari-Jacques SM, Hutz MH: Application of an African Ancestry Index as a genomic control approach in a Brazilian population. Ann. Hum. Genet. 70, 822-828 (2006).
16. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders Text Revision: DSM-IV-TR (4th Edition). APA, Washington DC, USA (1994).
17. McGuffin P, Farmer A, Harvey I: A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reability of the OPCRIT system. Arch. Gen. Psychiatry 48, 764-770 (1991).
18. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45, 789-796 (1988).
19. Overall JF, Gorham DR: The brief psychiatric rating scale. Psychol. Rep. 10, 799-812 (1962).
20. Brazilian Health Ministry: Protocolo Clinico e Diretrizes Tempêuticas: Esquizofrenia refratária. Brasília, Portaria no. 345 (2002).
21. Chong SA, Remington G: Clozapine augmentation: safety and efficacy. Schizophr. Bull. 26, 421-440 (2000).
22. Wong J, Delva N: Clozapine-induced seizures: recognition and treatment. Can. J. Psychiatry 52, 457-463 (2007).
23. Lahiri DK, Numberger JI: A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Research 19, 5444 (1991).
24. Rosskopf D, Busch S, Manthey I, Siffert W: G protein β3 gene: structure, promoter, and additional polymorphisms. Hypertension 36, 33-41 (2000).
25. Abramson JH, Gahlinger PM: Computer Programs for Epidemiologists: PEPI. (Version 4.0). Sagesbrush Press, UT, USA (2001).
26. Mattevi VS, Zembrzuski VM, Hutz MH: Impact of variation in ADRB2, ADRB3, and GNB3 genes on body mass index and waist circumference in a Brazilian population. Am. J. Hum. Biol. 18, 182-186 (2006).
27. Siffert W, Forster F, Jöckel KH et al.: Worldwide ethnic distribution of the G protein β3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and black African individuals. J. Am. Soc. Nephrol. 10, 1921-1930 (1999).
28. Lin CN, Tsai SJ, Hong CJ: Association analysis of a functional G protein β3 subunit gene polymorphism (C825T) in mood disorders. Neuropsychobiology 44, 118-121 (2001).
29. Kunugi H, Kato T, Fukuda R, Tatsumi M, Sakai T, Nanko S: Association study of C825T polymorphism of the G-protein b3 subunit gene with schizophrenia and mood disorders. J. Neural Transm. 109, 213-218 (2002).
30. Kitami T, Ernest S, Gallaugher L, Friedman L, Frankel WN, Nadeau JH: Genetic and phenotypic analysis of seizure susceptibility in PL/J mice. Mamm. Genome 15, 698-703 (2004).
31. Blednov YA, Stoffel M, Alva H, Harris RA: A pervasive mechanism for analgesia: activation of GIRK2 channels. Proc. Natl Acad. Sci. USA 100, 277-282 (2003).
32. + channel GIRK2. Proc. Natl Acad. Sci. USA 94, 923-927 (1997).
33. + (GIRK) channel expressed in Xenopus oocytes. Br. J. Pharmacol. 123, 421-426 (1998).
34. Hedges D, Jeppson K, Whitehead P: Antipsychotic medication and seizures: a review. Drugs Today 39, 551-557 (2003).
35. Devinsky O, Pacia SV: Seizures during clozapine therapy. J. Clin. Psychiatry 55, 153-156 (1994).
36. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions. A systematic review. JAMA 286, 2270-2279 (2001).